Table 6.
Event/GOLD | CAN/UK | ESP | SWE | ||||||
---|---|---|---|---|---|---|---|---|---|
| |||||||||
II | III | IV | II | III | IV | II | III | IV | |
No Ex | 0.79 | 0.75 | 0.65 | 0.82 | 0.72 | 0.57 | 0.73 | 0.74 | 0.52 |
Non-SevEx | 0.77 | 0.74 | 0.64 | 0.81 | 0.71 | 0.56 | 0.72 | 0.73 | 0.51 |
SevEx | 0.74 | 0.70 | 0.61 | 0.78 | 0.69 | 0.54 | 0.69 | 0.70 | 0.49 |
Notes: Weights for mild and moderate exacerbations were merged (averaged) if necessary to form “nonsevere exacerbation”. Utility weights were derived using the EQ-5D questionnaire. Data from Hettle et al26 (CAN/UK), Miravitlles et al49 (ESP), and Stahl et al50 (SWE).
Abbreviations: GOLD, Global Initiative for Chronic Obstructive Lung Disease; GOLD II, GOLD classification indicating moderate COPD; COPD, chronic obstructive pulmonary disease; GOLD III, GOLD classification indicating severe COPD; GOLD IV, GOLD classification indicating very severe COPD; CAN, Canada; ESP, Spain, SWE, Sweden; No Ex, no exacerbation; Non-SevEx, nonsevere exacerbation; SevEx, severe exacerbation; EQ-5D, Euroqol 5 dimension.